Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia

Inclusion Criteria

• •Men and women over the age of 18
• •Patients with chronic lymphoid leukemia and starting treatment with targeted therapy: ibrutinib, venetoclax or acalabrutinib, alone or in combination with obinutuzumab or rituximab in 1L or R/R according to the indications of the Marketing Authorization.
• •Be able to understand the objective and the constraints related to the research
• •Patient having signed the consent form
• •Patient with Social Security affiliation or equivalent
• •Person able to speak on the phone